RLYB (37) INO (34) QUCY (35) SDEV (42) ⌘ Pro Terminal →

Corbus Pharmaceuticals Holdings Inc. (CRBP) — RQD Stock Rating Cockpit

Q: Should I buy, hold, or sell CRBP stock right now?

Corbus Pharmaceuticals Holdings Inc. (CRBP) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

Q: What is CRBP's 12-month price target and RQD AI Jury consensus?

CRBP's 12-month base price target is $4.01 (range $3.13 to $13.52), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

$4.22 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $4.21

Corbus Pharmaceuticals Holdings Inc. (CRBP) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $81.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CRBP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CRBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $4.22 (0.00% 1D, market cap $81.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, CRBP ranks #352 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CRBP compare to RLYB and INO in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CRBP carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RLYB (Rallybio Corporation) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $83.0M) and INO (Inovio Pharmaceuticals Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $79.8M). Among the 5-stock peer group, CRBP leads on earnings multiple (N/A) while CRBP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CRBP?

▼

Per CRBP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001595097), Corbus Pharmaceuticals Holdings Inc. generated $0 in revenue, -$78.5M in net income, and -$64.5M in free cash flow against $168.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $4.21 (-0.19%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (47/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-5.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRBP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (47/100 Composite)

🔍 WHY CRBP SCORES 47/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (32% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 25.6 (OVERSOLD (<32))

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C$5.38-16% Next Q

Q2 (-2Q)

Grade C-$4.52-10.4% Next Q

Q3 (-1Q)

Grade C-$4.05+4.2% Next Q

Current

Grade D$4.22-5.9% Hist 90D α

Trajectory: C (55) → D (47)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CRBP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CRBP currently carries a cautious 47/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.17) and Max Pain ($4.43) forces dealer call-delta covering toward $13.52.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CRBP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “CRBP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 47%NO 53%Trade / Inspect Odds →

RSI-14 MOMENTUMOVERSOLD (<32)

25.630 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

2 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $4$4.22H: $13

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D-RQD 14 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: CRQD 25 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on CRBP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (48)

14/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like CRBP

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRBP)

✓Walkthrough of CRBP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRBP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -57.29%🛡️ HOLDING TREND SUPPORT

2026-10-30O $4.20H $4.31L $3.95C $4.22VOL 2.32M

RES: $10.88SUP: $3.61SMA50: $7.17SMA200: $8.62

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRBP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRBP Butterfly Map → + Track CRBP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRBP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRBP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRBP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRBP)

Health Care Rank #352 of 1016 ⚔️ RLYB vs CRBP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRBP vs. RLYB, INO, QUCY, SDEV)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Corbus Pharmaceuticals Holdings Inc. (CRBP) ranks #352 by composite RQD confidence (47/100, grade D) and #684 by equity capitalization ($81.6M). Within this direct 5-issuer industry benchmark cohort, CRBP leads on earnings valuation at N/A trailing P/E, while CRBP leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. CRBP currently leads its immediate peer cohort in composite quantitative strength at 47/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRBP ACTIVE Corbus Pharmaceuticals Holdings Inc.	D	47/100	—	—	-35.0%	0.00%	$81.6M	Benchmark Subject
RLYB Rallybio Corporation	D-	37/100	—	—	-35.0%	+0.84%	$83.0M	/rlyb-vs-crbp →
INO Inovio Pharmaceuticals Inc.	E	34/100	—	—	-35.0%	-21.95%	$79.8M	/ino-vs-crbp →
QUCY Quantum Cyber N.V.	D-	35/100	—	72.6%	-35.0%	-7.69%	$79.4M	/qucy-vs-crbp →
SDEV Stablecoin Development Corporation	D-	42/100	—	—	-35.0%	-6.48%	$79.0M	/sdev-vs-crbp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001595097

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Corbus Pharmaceuticals Holdings Inc. (CRBP) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$78.5M, operating cash flow of -$64.5M, and free cash flow of -$64.5M (-54.3% YoY). On the balance sheet, CRBP closed FY2025 with $168.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$78.5M	-$64.5M	-$64.5M	$168.2M	—
FY2024 (FY)	2024-12-31	$0	-$40.2M	-$41.8M	-$41.8M	$155.9M	—
FY2023 (FY)	2023-12-31	$0	-$44.6M	-$36.1M	-$36.1M	—	—

3. CRBP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRBP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does CRBP compare to RLYB and INO in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for CRBP?

Where is CRBP trading relative to its 50-day, 200-day, and 52-week technical levels?

CRBP last traded at $4.22 (0.00% on volume of 2,317,276 shares), positioning the stock -41.14% below its 50-day simple moving average ($7.17) and -51.04% below its 200-day simple moving average ($8.62). Across its 52-week range of $3.87 to $12.88, CRBP sits at the 3.9% percentile with a 14-day RSI of 25.6 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($3.69 to $4.75).

CRBP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell CRBP stock right now?

Corbus Pharmaceuticals Holdings Inc. (CRBP) currently earns a Roarable Rating of D (Sell — SELL) with 47/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is CRBP's 12-month price target and RQD AI Jury consensus?

CRBP's 12-month base price target is $4.01 (range $3.13 to $13.52), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: CRBP RQD Cockpit CRBP 12M Forecast CRBP Earnings & Move CRBP Dividends & DRIP CRBP Insiders & 13F CRBP Whale Options CRBP Profit Sankey CRBP News & Why

ROARABLE RATING BRIEF • RQD 47/100 (D) ✓ STAGE-C NUMBER FIREWALL VERIFIED

CRBP — Corbus Pharmaceuticals Holdings Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:44:54Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, CRBP scores 47 / 100, letter grade D, with the verdict "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

Fundamental Cash Engine: 8 / 20. Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this pillar reflects that the company is not generating returns on capital or free cash flow in the source data.
Whale 13F Flow: 9 / 20. Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. Holder-level detail is not available in the source data, so the score cannot be traced to specific filings in this dossier.
Insider Conviction: 5 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the second-weakest pillar and points to limited insider-side conviction in the score's own inputs.
Macro Regime Fit: 15 / 20. Per the Roarable RQD rating, beta is 1.0 with a sector-sensitivity component. This is the strongest pillar and indicates market-relative sensitivity roughly in line with the broad market.
Forensic Balance Sheet: 10 / 20. Per the Roarable RQD rating, the Altman Z is 2.5, Piotroski F is 2/9, and Debt/Equity is 0.5. These are mixed-to-weak forensic readings.

Taken together, the low pillar scores for cash generation, insider conviction, and forensic strength drive the D grade. For a prospective investor, the upside case rests mainly on the fact that the stock trades well below its 52-week high and that the macro pillar is comparatively neutral. The valuation tradeoff is that with no positive earnings or free cash flow in the source data, traditional earnings-based valuation cannot be anchored. The downside risk is that the rating itself signals a distribution warning. This is educational analysis, not personalized financial advice.

Business

Corbus Pharmaceuticals Holdings Inc. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, its market capitalization is $0.1B. Per the SEC financials, reported revenue is $0.0M for FY 2025, FY 2024, and FY 2023, so the source data does not show a revenue-generating customer base. Not available in source data: a product list, customer identities, or the company's monetization model beyond the absence of reported revenue.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$0.0M	$-85.3M	$-78.5M	N/A	$-64.5M	$28.5M	N/A
FY 2024	$0.0M	$-48.7M	$-40.2M	N/A	$-41.8M	$17.2M	N/A
FY 2023	$0.0M	$-45.1M	$-44.6M	N/A	$-36.1M	N/A	N/A

Per the SEC financials, operating losses widened from $-45.1M in FY 2023 to $-85.3M in FY 2025, and net losses followed the same direction. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. Reported cash rose to $28.5M in FY 2025, but Not available in source data: debt levels for the reported periods.

Recent Catalysts & News Wire Analysis

Green catalyst (MarketWatch, "outperforms competitors on strong trading day"): Flagged as CATALYST in the news feed. The source does not provide the underlying trading or fundamental driver.
Yellow market wire (TradingView, "Estimates"): Flagged as MARKET WIRE. The headline title references estimates, but the source does not provide estimate values.
Red risk watch (Simply Wall St, "Insiders Lose Out As Stock Sinks To US$5.38"): Flagged as RISK WATCH. The headline points to insider underperformance and a price of US$5.38, which is above the current price of 4.22 in market data; the source does not reconcile the two figures.
Yellow market wire (Stock Titan, "Two investors report zero shares"): Flagged as MARKET WIRE. Details are not in the source data.
Yellow market wire (MarketWatch, "underperforms Monday"): Flagged as MARKET WIRE. The source does not give the performance magnitude.
Green catalyst (MarketWatch, "outperforms competitors on strong trading day"): Flagged as CATALYST, a second instance of the same headline.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

Open Questions

What are the underlying drivers and product pipeline behind the reported $0.0M revenue and the widening operating losses?
What is the reported debt balance, given that debt is N/A across all three periods and Debt/Equity is cited as 0.5?
How does the US$5.38 figure in the Simply Wall St headline reconcile with the current price of 4.22?
What specific insider and institutional transactions underlie the Insider Conviction and Whale 13F Flow pillar scores?
What is the company's cash runway given FY 2025 FCF of $-64.5M against reported cash of $28.5M?

CRBP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Corbus Pharmaceuticals Holdings Inc. (CRBP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CRBP Debate Forum (3) ↓

🟢 CATALYST MarketWatch • 1h ago

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day

MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 4h ago

Corbus Pharmaceuticals Holdings, Inc. Estimates – NASDAQ:CRBP

TradingView report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Simply Wall St • 7h ago

Corbus Pharmaceuticals Holdings Insiders Lose Out As Stock Sinks To US$5.38

Simply Wall St report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 10h ago

Two investors report zero shares in Corbus Pharmaceuticals (CRBP).

Stock Titan report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketWatch • 13h ago

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors

MarketWatch report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 19h ago

Corbus Pharmaceuticals (CRBP) Slides 9.3% to $4.78, Nearing Key Support at $4.54 - Wave Equality

https://www.siam.in/ report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE ad-hoc-news.de • 22h ago

Corbus schedules November 11 results: Corbus Pharmaceuticals stock sits 76.80 percent below its high

ad-hoc-news.de report covering Corbus Pharmaceuticals Holdings Inc. (CRBP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo • 11d ago

Corbus Pharmaceuticals to Present Late Breaking CRB-913 Data from Canyon-1 Study at Obesity Week® 2026

NORWOOD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical-stage company focused on new therapies in oncology and obesity, today announced that late breaking data f

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CRBP Bull vs. Bear Conversation Board — What's Your Call at $4.22?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CRBP 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $4.56 (+8.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is CRBP (D • RQD 47/100) a Buy at $4.22?

Welcome to the CRBP (Corbus Pharmaceuticals Holdings Inc.) Roar Pit. Current RQD Composite is 47/100 (Roarable Sell — Underperform / Distribution Warning) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

RE RedlineAuditor Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $3.54 (-16.1%)

Spot @ $4.22

Pump the brakes on CRBP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on CRBP, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Corbus Pharmaceuticals Holdings Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH 🎯 Target: $4.81 (+14.0%)

Spot @ $4.22

CRBP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on CRBP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $4.22 (52-wk range $3.87 - $12.88), any beat on forward guidance forces shorts and underweight funds to chase.